Clinical value of biomarkers in diagnosis and treatment of idiopathic pulmonary fibrosis.
10.12122/j.issn.1673-4254.2020.07.23
- Author:
Yubin FAN
1
,
2
;
Rongling HE
1
,
2
;
Lijun ZOU
1
,
2
;
Jie MENG
1
,
2
Author Information
1. Department of Respiratory and Critical Care Medicine, Xiangya Hospital
2. Organ Fibrosis Research Center, Central South University, Changsha 410008, China.
- Publication Type:Journal Article
- Keywords:
Idiopathic pulmonary fibrosis;
biomarker;
diagnosis;
prognosis
- MeSH:
Amino Acid Oxidoreductases;
Biomarkers;
Disease Progression;
Humans;
Idiopathic Pulmonary Fibrosis;
Intracellular Signaling Peptides and Proteins;
Matrix Metalloproteinase 7;
Prognosis
- From:
Journal of Southern Medical University
2020;40(7):1062-1065
- CountryChina
- Language:Chinese
-
Abstract:
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial pneumonia characterized by progressive accumulation of fibroblastic foci and destruction of the alveolar structure. Due to an incomplete understanding of the mechanism of the occurrence and progression of IPF, currently no effective means have been available for its early screening or treatment. With a poor overall prognosis, the patients with IPF have a median survival of only 2-4 years. In recent years, several studies have confirmed that dozens of molecules are involved in the development of IPF and can be used as potential biomarkers. These biomarkers play important roles in early diagnosis (such as SP-D, MMP-7, and osteopontin), prognostic evaluation (such as telomerase length, KL-6, mtDNA, HSP-70, LOXL2, CXCL13, miRNA, ICAM-1, and CCL18), and guiding treatment of IPF (such as TOLLIP rs3750920 genotype, SAMS score, and SP-D), and also provide potential therapeutic targets (such as TERT, TERR, RTEC, and PARN).
